SMS Lifesciences Reports Decline in Profitability and Operational Efficiency in March 2025 Results

SMS Lifesciences India, a microcap player in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's financial standing, as reflected in the recent evaluation changes.
The Profit Before Tax less Other Income (PBT) for the quarter stands at Rs 1.59 crore, marking a significant decline compared to the previous year. Similarly, the Profit After Tax (PAT) has also shown a downward trend, recorded at Rs 2.97 crore. This decline in profitability is further underscored by the operating profit metrics, with the Operating Profit (PBDIT) reaching its lowest point in the last five quarters at Rs 7.42 crore.

Additionally, the Operating Profit Margin has decreased to 8.33%, indicating challenges in operational efficiency. The company's ability to manage interest payments is also under scrutiny, as the Operating Profit to Interest ratio has fallen to 3.66 times, the lowest in recent quarters. Furthermore, a substantial portion of the income is derived from non-operating sources, which raises concerns about the sustainability of the business model.

Overall, SMS Lifesciences has experienced a revision in its score, reflecting the current financial landscape.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.